NPM1 and acute myeloid leukemia: We also analyzed the potentiality of ASXL1 mutations as prognostic markers in subgroups of AML cases presenting with intermediate-risk cytogenetic profiles and NPM1 mutations and intermediate-risk cytogenetic profiles without NPM1 mutations.